UNIVERSAL HEALTH SERVICES INC Q3 FY2026 earnings call

• Acute Care Demand & Capacity: Underlying demand remained favorable with broad-based geographic strength. Investments in acute care capacity, including 177 new beds added in Q2, are ramping through year-end. One freestanding emergency department opened in Q3 and another in Q4. Ambulatory development pipelines are expanding outpatient access points.
• Behavioral Health Integration (Talkspace): The Talkspace acquisition closed on August 17, 2026. Integration is proceeding via three work streams: deploying technology platforms for smoother care transitions, establishing referral flows from UHS facilities to Talkspace, and developing flexible virtual intensive outpatient programs (IOP). Synergies are expected to materialize over the next 12-24 months.
• Laurel Ridge Recertification: The team continues working with regulators to recertify the San Antonio facility, expected during 2027. Q3 financial impact aligned with prior outlook assumptions.
• De Novo Hospital Progress: Palm Beach Gardens (Florida) startup losses improved monthly, with expectations for acceleration during Florida’s winter season. Cedar Hill (Washington, D.C.) operating losses were stable sequentially; break-even is now expected in H1 2027 due to slower-than-anticipated physician practice development in the community.
• Expense Management: Labor trends moderated, with headcount growth decelerating in behavioral health and temporary/traveling labor reduced in acute care. Supply expenses decreased per adjusted admission.

Acute Care: Same-facility net revenue increased 4.7% year-over-year, driven by a 4.9% increase in adjusted admissions and a 4.6% rise in emergency department visits, partially offset by a 0.7% decline in surgeries. Same-facility segment EBITDA declined 4.5%, though it grew 2.9% when excluding out-of-period supplemental payment benefits. Revenue per adjusted admission decreased 1.7% on a reported basis due to a shift toward lower-acuity medical admissions over surgical cases and exchange volume declines; underlying rate growth was approximately 3%. Behavioral Health: Same-facility net revenue increased 4.0%, supported by a 2.1% increase in adjusted patient days and a 2.1% increase in revenue per patient day. Volumes improved modestly relative to recent quarters. The segment results included immaterial contributions from Talkspace (due to mid-quarter acquisition timing) and startup losses from two de novo projects, as well as ongoing operating losses at Laurel Ridge.

• Reiterated 2026 Outlook: Management reiterated the financial and operating forecast ranges issued in July 2026. Results are expected towards the lower end of these ranges due to the gradual ramp-up of de novo hospitals and other near-term variables.
• 2027 Headwinds Estimated: Medicaid supplemental payments (DPP) are projected to create a $175–$200 million headwind in 2027, primarily reflecting non-recurring benefits recorded in 2026 and initial OB-3 provider tax impacts. Exchange volumes are expected to contribute a ~$15 million annualized headwind based on H2 2026 run rates, with potential for further increases depending on enrollment.
• 2027 Tailwinds Expected: Potential recovery of operating losses from underperforming facilities (Laurel Ridge, Cedar Hill, Palm Beach Gardens), which cumulatively lost $80–$100 million in 2026, may provide significant margin improvement in 2027.
• Capital Expenditures: Full-year 2026 CapEx is anticipated to be slightly below $1 billion. Beyond 2026, CapEx is expected to moderate toward $800 million annually as major de novo projects complete.
• Share Repurchases: Company remains active in share repurchases, with $735 million authorization remaining as of September 30, 2026.

• Regulatory Changes: Significant uncertainty surrounding Medicaid work requirements, which could lag implementation by up to six months. Medical frailty exemptions remain a key open item affecting behavioral health and acute care volumes in expansion states.
• Medicaid Supplemental Payment Reductions: Anticipated reductions in state-directed payments (SDP) and provider taxes due to OB-3 legislation will create substantial earnings headwinds starting in late 2027 and extending into 2028.
• Exchange Volume Volatility: Continued disenrollment or policy changes affecting health insurance exchanges pose a risk to volume and pricing, with potential for headwinds exceeding current estimates.
• De Novo Ramp-Up Delays: Slower-than-expected maturation of new hospitals (Cedar Hill, Palm Beach Gardens) delays margin improvement and extends loss periods.
• Surgical Mix Shift: Accelerated shift of procedures to alternative settings (ASCs, physician offices) negatively impacts surgical volumes and creates staffing challenges for ER coverage in certain specialties like GI.
• Litigation Costs: Non-recurring litigation and transaction costs, including professional liability reserves, may impact reported results.

Q: What are the key puts and takes for 2027 guidance, specifically regarding Medicaid DPP headwinds and exchange impacts? / A: CFO Steve Filton noted that full 2027 guidance will be issued in February. Key headwinds include a $175–$200 million drop in Medicaid supplemental payments (largely non-recurring 2026 benefits) and a ~$15 million annualized exchange headwind. Tailwinds include potential loss recovery from underperforming facilities like Laurel Ridge and de novo hospitals, which lost $80–$100 million in 2026 but may improve significantly in 2027 as Laurel Ridge regains certification and de novos ramp.

Q: What is driving the slower-than-expected ramp at the Cedar Hill and Palm Beach Gardens de novo hospitals? / A: Cedar Hill’s delay is attributed to a lack of existing physician infrastructure in Ward 7/8 of Washington, D.C., requiring time to attract and develop local practices. Palm Beach Gardens opened in summer instead of peak season due to construction delays, causing a slower start, but volumes are improving monthly and expected to accelerate in winter. Both facilities remain structurally sound, just maturing slower than initially projected.

Q: How does the shift from surgical to medical admissions affect acute care pricing and strategy? / A: The shift is an industry-wide acceleration of procedures moving to outpatient settings (ASCs/physician offices), particularly in GI and orthopedics. This mix change pressured revenue per admission by ~100 bps. However, management views this as unavoidable market dynamics rather than a strategic choice. They continue investing in procedural capabilities (robotics, OR capacity) and outpatient access points to capture referrals, aiming to grow both overall volumes and surgical volumes despite the trend.

Q: What are the integration synergies and timeline for the Talkspace acquisition? / A: Talkspace was acquired to create a unique continuum of care, linking UHS’s higher-acuity patients with Talkspace’s lower-acuity population. Revenue synergies, such as referring UHS patients to Talkspace and vice versa, are expected to begin materializing in the second half of 2027 (12–24 months post-close). Initial overhead savings are minimal; the primary value lies in expanded outpatient offerings and cross-referral pathways. Integration is underway across technology, referral flows, and virtual IOP development.

Q: How should investors view the health plan’s contribution and MLR trends? / A: The Medicare Advantage plan, which comprises ~90% of its revenue, contributed a ~$25 million tailwind in 2026 due to MLR improvements. It operates only in markets with UHS acute care hospitals, providing strategic support to hospital volumes. For 2027, no material earnings impact is expected beyond normal growth. The plan maintains low pre-tax margins historically, serving more as a volume driver and payer relationship tool than a standalone profit center.